Department of Urology, 928th Hospital of PLA Joint Logistic Support Force, Haikou, China.
Department of Urology, Hainan Hospital of PLA General Hospital, Sanya, China.
Neoplasma. 2020 Nov;67(6):1314-1318. doi: 10.4149/neo_2020_191130N1234. Epub 2020 Jul 1.
Predictive biomarkers for early diagnosis of prostate cancer are important for its treatment. The functional microRNAs in the exosomes of plasma and serum samples are of interest as stable and non-invasive biomarkers for recurrence in cancer patients. The present study aimed to clarify the value of plasma exosomal miRNA-125a-5p and miR-141-5p as biomarkers for the diagnosis of prostate cancer. The study included 19 healthy individuals and 31 prostate cancer patients. In comparison to the levels in healthy controls, exosomal miR-141-5p levels showed a slight increase in prostate cancer patients (p=0.085), and miR-125a-5p levels that showed a significant decrease in patients with prostate cancer than in healthy controls (p=0.032). As a derived parameter, the miR-125a-5p/miR-141-5p ratio was significantly higher in patients with prostate cancer than in healthy controls (p<0.001). We found that exosomal miR-141-5p in plasma showed a promise in distinguishing prostate cancer patients with the AUC of 0.652, and for miR-125a-5p, the AUC was 0.691. For the miR-125a-5p/miR-141-5p ratio, the AUC value was 0.793. We found that miR-125a-5p has a weak positive correlation with PSA (correlation coefficient = 0.3413). Moreover, miR-141-5p has been found to hold a negatively no-significant correlation with PSA, with the correlation coefficient is -0.1102. We speculate that, as diagnostic markers for prostate cancer, miR-125-5p and miR-141-5p might be independent of the PSA. In summary, the results of this study suggest that high plasma exosomal expression of miR-141-3p and low expression of miR-125a-5p in plasma exosomes from prostate cancer patients might be useful markers of specific tumor traits associated with prostate cancer. Moreover, the miR-125a-5p/miR-141-5p ratio seems to perform better than either of the single values alone.
用于前列腺癌早期诊断的预测性生物标志物对于其治疗很重要。血浆和血清样本外泌体中的功能性 microRNA 作为癌症患者复发的稳定且非侵入性生物标志物受到关注。本研究旨在阐明血浆外泌体 miRNA-125a-5p 和 miR-141-5p 作为前列腺癌诊断生物标志物的价值。该研究纳入了 19 名健康个体和 31 名前列腺癌患者。与健康对照组相比，外泌体 miR-141-5p 水平在前列腺癌患者中略有升高（p=0.085），而 miR-125a-5p 水平在前列腺癌患者中显著低于健康对照组（p=0.032）。作为衍生参数，前列腺癌患者的 miR-125a-5p/miR-141-5p 比值明显高于健康对照组（p<0.001）。我们发现，血浆外泌体 miR-141-5p 在区分前列腺癌患者方面具有一定的潜力，其 AUC 为 0.652，而对于 miR-125a-5p，AUC 为 0.691。对于 miR-125a-5p/miR-141-5p 比值，AUC 值为 0.793。我们发现，miR-125a-5p 与 PSA 呈弱正相关（相关系数=0.3413）。此外，miR-141-5p 与 PSA 呈负相关但无统计学意义，相关系数为-0.1102。我们推测，miR-125-5p 和 miR-141-5p 作为前列腺癌的诊断标志物可能与 PSA 无关。综上所述，本研究结果表明，前列腺癌患者血浆外泌体中 miR-141-3p 的高表达和 miR-125a-5p 的低表达可能是与前列腺癌相关的特定肿瘤特征的有用标志物。此外，miR-125a-5p/miR-141-5p 比值似乎比单一值的表现更好。
